Urologic oncology · 2026
KDM6A suppresses proliferation and epithelial-mesenchymal transition in prostate cancer cells.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ni Yixiu, Lin Yijia, Wang Wankun, Bao Yizhong, Chen Jun
Аннотация
BACKGROUND AND OBJECTIVE: Prostate cancer is one of the most common male malignancies worldwide. KDM6A, a histone H3K27 demethylase, has been implicated in various cancers; however, its specific functions in prostate cancer remain controversial. This study aimed to investigate the regulatory role of KDM6A in castration-resistant prostate cancer (CRPC).
METHODS: We analyzed the GEO public database and conducted in vitro and in vivo experiments to examine the function of KDM6A in CRPC.
RESULTS: KDM6A expression was downregulated in CRPC compared with primary prostate cancer. KDM6A acted as a tumor suppressor; its depletion promoted proliferation and migration of prostate cancer cells both in vitro and in vivo. Suppression of KDM6A activated epithelial-mesenchymal transition (EMT) via HMGB2, thereby regulating the invasive behavior of prostate cancer. EMT is known to play a critical role in CRPC progression.
CONCLUSIONS: Our findings reveal the functional role of KDM6A in CRPC and suggest its potential utility in exploring novel therapeutic strategies for CRPC.
METHODS: We analyzed the GEO public database and conducted in vitro and in vivo experiments to examine the function of KDM6A in CRPC.
RESULTS: KDM6A expression was downregulated in CRPC compared with primary prostate cancer. KDM6A acted as a tumor suppressor; its depletion promoted proliferation and migration of prostate cancer cells both in vitro and in vivo. Suppression of KDM6A activated epithelial-mesenchymal transition (EMT) via HMGB2, thereby regulating the invasive behavior of prostate cancer. EMT is known to play a critical role in CRPC progression.
CONCLUSIONS: Our findings reveal the functional role of KDM6A in CRPC and suggest its potential utility in exploring novel therapeutic strategies for CRPC.